In summary, we showed that ctDNA analysis with the tumor-informed approach outperforms the tumor-agnostic approach with higher analytical sensitivity, lower probability of false-positive results due to CH mutations, and improved sensitivity in detecting recurrence in resected CRC patients. This evidence concerns the gene C4B and neoplasm.